> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CGMP Violations at Amneal Gujarat, India
- URL: https://www.fdaweb.com/cgmp-violations-at-amneal-gujarat-india/
- Published: 2025-09-03T12:00:00.000Z
- Updated: 2026-09-14T15:20:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159802

A 3/10-3/19 FDA inspection at the Amneal Pharmaceuticals drug manufacturing facility in Gujarat, India, found significant violations of current good manufacturing practice (CGMP) regulations for finished drugs. An 8/27 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amneal-pharmaceuticals-llc-709894-08272025?ref=fdaweb.com) says the specific violations were:

- failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed; and
- failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to ensure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.

FDA says that significant findings in the letter indicate that the firm’s quality unit is not fully exercising its authority and/or responsibilities. “Your firm must provide the quality unit with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality,” it says.

Amneal was told to correct the violations promptly and to respond with a list of specific actions it has taken to address the violations and prevent their recurrence, with a schedule for completing the corrections.